Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms

Anderson, D; Lyman, Stewart D.; Baird, Allison Michelle; Wignall, J; Eisenman, June; Rauch, Charles T.; March, Carl J.; Boswell, H. Scott; Gimpel, Steven D.; Cosman, David; Williams, Douglas E.

doi:10.1016/0092-8674(90)90304-w

Cited by 793 publications

(321 citation statements)

References 45 publications

Supporting

Mentioning

313

Contrasting

Unclassified

Order By: Relevance

“…SCF, the ligand for c-kit, enhances the growth of primitive hematopoietic progenitor cells synergistically with hematopoietic growth factors such as IL-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte colonystimulating factor in vitro [9][10][11]. These results suggest that SCF and c-kit system play an important role in early hematopoiesis.…”

Section: Discussionmentioning

confidence: 94%

“…These results suggest that SCF and c-kit system play an important role in early hematopoiesis. Anderson et al have shown two forms of SCF that arise through differential RNA processing: a membrane-bound form and a soluble secreted form [11]. The transfected COS cells expressing murine surface SCF adhered with murine mast cells, suggesting that the membrane-bound molecule may act as an adhesion molecule [26].…”

Section: Discussionmentioning

confidence: 99%

“…The proto-oncogene c-kit [7,8], which is a receptor for stem cell factor (SCF) [9][10][11][12][13][14], plays a critical role in early hematopoiesis. Mutations at the murine dominant-white spotting locus that maps to c-kit cause severe anemia [15].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Down‐modulation of c‐kit mRNA and protein expression by erythroid differentiation factor/activin A

et al. 1995

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Down‐modulation of c‐kit mRNA and protein expression by erythroid differentiation factor/activin A

et al. 1995

View full text Add to dashboard Cite

“…When the c-Kit receptor binds with human stem cell factor (SCF), also termed cKit ligand, which is produced by mesenchymal cells, it will augment the proliferation of primitive bone marrow progenitor cells and differentiated mast cells. [13][14][15] The fibroblast-like stem cells express the c-Kit, suggestive of mesenchymal differentiation. STRO-1 is a monoclonal antibody that has been shown to recognize all the clonogenic mesenchymal stem cells in human bone marrow.…”

Section: Discussionmentioning

confidence: 99%

Involvement of bone marrow-derived stem and progenitor cells in the pathogenesis of pterygium

Song

Kang

et al. 2004

Eye

View full text Add to dashboard Cite

Aims To evaluate the involvement of multipotential stem and progenitor cells in the pathogenesis of pterygium. Methods Paraffin-embedded and snap-frozen primary pterygium (n ¼ 10) were serially sectioned and analysed immunohistochemically to determine the expression level of AC133 (marker for the primitive haematopoietic progenitors), CD34 (marker for the haematopoietic progenitor cells and endothelium), c-Kit (marker for haematopoietic and stromal progenitor cells), and STRO-1 (a differentiation antigen present on bone marrow fibroblast cells and on various nonhaematopoietic progenitor cells). Results In all the primary pterygium, immunoreactivity of AC133 and STRO-1 was found in some of the epithelial and stromal cells, CD34 was observed in the vascular endothelium, and some scattered ovoidal cells were found in the subepithelial connective tissue. C-Kit was expressed mainly in the basal epithelium of the head portions, and some spindle-shaped stromal cells. There is no immunoreactivity of AC133, c-Kit, and STRO-1 in normal conjunctiva, whereas CD34 was mildly stained with vessel wall. Conclusion Multipotential stem and progenitor cells may be involved in the pathogenesis of pterygium through its differentiation into fibroblasts and vascular endothelial cells.

show abstract

“…Similar to G-CSF and GM-CSF, SCF is a hematopoietic factor that is well known to regulate proliferation, differentiation and survival of bone marrow derived stem cells 72, 73 Orlic et al was the first to use a combined therapy of G-CSF and SCF in a murine model of MI and demonstrated a significant improvement in LV remodelling, cardiac function, and animal survival with five days of treatment 33 . Improved outcome was associated with significant bone marrow derived cardiomyogenesis 33 These results, however, were not reproduced when G-CSF and SCF were given as a single dose at 4 hours following MI to non-human primates 74 While G-CSF and SCF/c-kit represent important factors for the recruitment of bone marrow derived stem cells following MI, actual results from various groups have been controversial at best; owing to the timing of cytokine administration and the dose utilized, as well as the actual model system.…”

Section: G-csf and Scf/c-kitmentioning

confidence: 99%

The Bone Marrow—Cardiac Axis of Myocardial Regeneration

Liao

Pfister

Jain

et al. 2007

Progress in Cardiovascular Diseases

View full text Add to dashboard Cite

Congestive heart failure remains the leading cause of morbidity and mortality in the developed world. Current therapies do not address the underlying pathophysiology of this disease, namely the progressive loss of functional cardiomyocytes. The notion of repairing or regenerating lost myocardium via cell based therapies remains highly appealing. The recent identification of adult stem cells, including both cardiac stem/progenitor cells and bone marrow stem cells, has triggered an explosive interest in utilizing these cells for physiologically relevant cardiomyogenesis. Enthusiasm for cardiac regeneration via cell therapy has further been fueled by the many encouraging reports in both animals and human studies. Further intensive research in basic science and clinical arenas are needed in order to make this next great frontier in cardiovascular regenerative medicine a reality. In this review, we focus on the role of bone marrow derived stem cells and cardiac stem/ progenitor cells in cardiomyocyte homeostasis and myocardial repair and regeneration, as well as provide a brief overview of current clinical trials utilizing cell-based therapeutic approaches in patients with heart disease.Despite advances in the treatment of congestive heart failure (CHF), morbidity and mortality remain inappropriately high 1 This medical epidemic has only continued to escalate, given an overall aging population and the greater number of patients surviving an initial myocardial infarction (MI). The pathophysiology of post-MI heart failure is driven by the loss of cardiomyocytes, either due to acute ischemic necrosis or chronic apoptosis, and the inability of the remaining cardiomyocytes to adequately compensate. As such, the concept of repairing or regenerating lost myocardium via cell based therapies (so termed "cardiomyoplasty") remains highly appealing. Over the past decade, much research has focused upon identifying the ideal cell type with which to promote myocardial regeneration. Thus far, several cells types have been investigated in animal models including, but not limit to, fetal cardiomyocytes 2, 3 , fibroblasts, skeletal myoblasts 4-7 and endothelial progenitor cells 8,9 . Results with all these cell types have generally been encouraging with regards to beneficial post-MI remodeling; albeit none have resulted in definitive differentiation into physiologically-significant, forcegenerating cardiomyocytes. Five years ago, striking reports suggested, for the first time, that bone marrow derived stem cells (hematopoietic stem cells) may have the potential to regenerate significant amounts of lost myocardium in mice following MI 10,11 , creating overwhelmingly enthusiasm and subsequent skepticism in the field of cardiac repair and regeneration. More recently, the identification of resident cardiac stem/progenitor cells by several groups, including ours 12-15 , has brought about a second wave of the scientific interest. These findings have advanced our understanding of myocardial biology and physiology and have introduced P...

show abstract

Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms

Cited by 793 publications

References 45 publications

Down‐modulation of c‐kit mRNA and protein expression by erythroid differentiation factor/activin A

Down‐modulation of c‐kit mRNA and protein expression by erythroid differentiation factor/activin A

Involvement of bone marrow-derived stem and progenitor cells in the pathogenesis of pterygium

The Bone Marrow—Cardiac Axis of Myocardial Regeneration

Contact Info

Product

Resources

About